| Nome |
# |
|
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, file e27ce426-e257-2581-e053-d805fe0acbaa
|
2.701
|
|
High-dose Vitamin C enhances cancer immunotherapy, file e27ce42f-de1f-2581-e053-d805fe0acbaa
|
2.293
|
|
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial, file e27ce42a-9a18-2581-e053-d805fe0acbaa
|
1.962
|
|
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma., file e27ce426-f515-2581-e053-d805fe0acbaa
|
1.549
|
|
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer, file e27ce430-1013-2581-e053-d805fe0acbaa
|
1.087
|
|
Adaptive mutability of colorectal cancers in response to targeted therapies, file e27ce42e-f361-2581-e053-d805fe0acbaa
|
873
|
|
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file e27ce42c-7e04-2581-e053-d805fe0acbaa
|
749
|
|
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer, file e27ce426-f447-2581-e053-d805fe0acbaa
|
671
|
|
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution., file e27ce427-09bb-2581-e053-d805fe0acbaa
|
552
|
|
BRAF V600E is a determinant of sensitivity to proteasome inhibitors., file e27ce426-ffd1-2581-e053-d805fe0acbaa
|
482
|
|
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities, file e27ce428-d7aa-2581-e053-d805fe0acbaa
|
430
|
|
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, file e27ce42c-ac40-2581-e053-d805fe0acbaa
|
403
|
|
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer, file e27ce42e-fdba-2581-e053-d805fe0acbaa
|
361
|
|
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer, file e27ce42c-833b-2581-e053-d805fe0acbaa
|
326
|
|
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies, file e27ce426-f0f2-2581-e053-d805fe0acbaa
|
313
|
|
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model, file e27ce426-9df8-2581-e053-d805fe0acbaa
|
308
|
|
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer, file e27ce42b-4659-2581-e053-d805fe0acbaa
|
301
|
|
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer, file e27ce427-2d1b-2581-e053-d805fe0acbaa
|
291
|
|
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs, file e27ce428-9f58-2581-e053-d805fe0acbaa
|
272
|
|
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma, file e27ce42b-34b3-2581-e053-d805fe0acbaa
|
265
|
|
Minimal residual disease in breast cancer: in blood veritas., file e27ce426-f514-2581-e053-d805fe0acbaa
|
256
|
|
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets, file e27ce426-9d7d-2581-e053-d805fe0acbaa
|
243
|
|
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-ad33-2581-e053-d805fe0acbaa
|
236
|
|
Sensitivity to Entrectinib Associated with a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer, file e27ce428-9c8e-2581-e053-d805fe0acbaa
|
233
|
|
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions, file e27ce42b-9069-2581-e053-d805fe0acbaa
|
229
|
|
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer, file e27ce426-d50c-2581-e053-d805fe0acbaa
|
223
|
|
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, file e27ce42a-9432-2581-e053-d805fe0acbaa
|
216
|
|
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo letter, file e27ce42e-896e-2581-e053-d805fe0acbaa
|
205
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce428-9706-2581-e053-d805fe0acbaa
|
204
|
|
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer, file e27ce42b-fd7d-2581-e053-d805fe0acbaa
|
204
|
|
Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature, file e27ce42c-9a05-2581-e053-d805fe0acbaa
|
193
|
|
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients, file e27ce427-0386-2581-e053-d805fe0acbaa
|
188
|
|
Exploiting DNA repair defects in colorectal cancer, file e27ce42d-e5d7-2581-e053-d805fe0acbaa
|
188
|
|
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file e27ce428-ee7a-2581-e053-d805fe0acbaa
|
184
|
|
Somatic alterations as the basis for resistance to targeted therapies, file e27ce428-9f6e-2581-e053-d805fe0acbaa
|
179
|
|
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells., file e27ce426-f1b3-2581-e053-d805fe0acbaa
|
172
|
|
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients, file e27ce435-9a5d-2581-e053-d805fe0acbaa
|
171
|
|
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers, file e27ce428-9c1b-2581-e053-d805fe0acbaa
|
166
|
|
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, file e27ce426-de44-2581-e053-d805fe0acbaa
|
165
|
|
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells., file e27ce427-09b7-2581-e053-d805fe0acbaa
|
164
|
|
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance., file e27ce427-09b8-2581-e053-d805fe0acbaa
|
162
|
|
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases, file e27ce42c-7e06-2581-e053-d805fe0acbaa
|
161
|
|
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer, file ec9c2092-a53b-4286-be12-aa515de4f3e9
|
152
|
|
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway, file e27ce428-9ade-2581-e053-d805fe0acbaa
|
149
|
|
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology, file e27ce42e-7735-2581-e053-d805fe0acbaa
|
149
|
|
Mutational profiling of kinases in glioblastoma., file e27ce427-09ba-2581-e053-d805fe0acbaa
|
147
|
|
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, file e27ce428-f6ea-2581-e053-d805fe0acbaa
|
145
|
|
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS, file e27ce426-d43e-2581-e053-d805fe0acbaa
|
144
|
|
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file e27ce42c-4ba9-2581-e053-d805fe0acbaa
|
143
|
|
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer, file e27ce426-b3ca-2581-e053-d805fe0acbaa
|
135
|
|
Preclinical models for precision oncology, file e27ce42e-972c-2581-e053-d805fe0acbaa
|
134
|
|
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, file e27ce42b-34b0-2581-e053-d805fe0acbaa
|
131
|
|
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case, file e27ce42c-564d-2581-e053-d805fe0acbaa
|
131
|
|
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia, file e27ce426-e4f1-2581-e053-d805fe0acbaa
|
130
|
|
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, file e27ce42a-d37f-2581-e053-d805fe0acbaa
|
129
|
|
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients, file e27ce42a-d380-2581-e053-d805fe0acbaa
|
129
|
|
Evolving neoantigen profiles in colorectal cancers with DNA repair defects, file e27ce42e-a91a-2581-e053-d805fe0acbaa
|
128
|
|
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group, file e27ce433-cdb4-2581-e053-d805fe0acbaa
|
125
|
|
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients, file e27ce42b-34b5-2581-e053-d805fe0acbaa
|
123
|
|
Early-onset colorectal cancer in young individuals, file e27ce42d-e4e5-2581-e053-d805fe0acbaa
|
119
|
|
Toward understanding and exploiting tumor heterogeneity, file e27ce428-d0ff-2581-e053-d805fe0acbaa
|
113
|
|
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer, file e27ce42f-ed2c-2581-e053-d805fe0acbaa
|
113
|
|
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies, file e27ce42d-8304-2581-e053-d805fe0acbaa
|
107
|
|
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer, file e27ce435-6233-2581-e053-d805fe0acbaa
|
106
|
|
How liquid biopsies can change clinical practice in oncology, file e27ce42f-a2de-2581-e053-d805fe0acbaa
|
104
|
|
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance, file e27ce42c-b2a5-2581-e053-d805fe0acbaa
|
102
|
|
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib., file e27ce42e-9c36-2581-e053-d805fe0acbaa
|
102
|
|
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial, file e27ce430-cb73-2581-e053-d805fe0acbaa
|
100
|
|
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects., file e27ce426-bd45-2581-e053-d805fe0acbaa
|
98
|
|
Exploring the links between cancer and placenta development, file e27ce42d-687c-2581-e053-d805fe0acbaa
|
98
|
|
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer, file e27ce430-7fc7-2581-e053-d805fe0acbaa
|
97
|
|
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file e27ce429-176a-2581-e053-d805fe0acbaa
|
95
|
|
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy., file e27ce426-df59-2581-e053-d805fe0acbaa
|
94
|
|
Inactivation of DNA repair-prospects for boosting cancer immune surveillance, file e27ce42d-b681-2581-e053-d805fe0acbaa
|
94
|
|
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer, file e27ce42c-9243-2581-e053-d805fe0acbaa
|
91
|
|
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors, file 2a9b9aad-9b03-41b3-9423-b8b115aae403
|
87
|
|
TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma, file e27ce42f-6ed8-2581-e053-d805fe0acbaa
|
86
|
|
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer, file e27ce429-c87b-2581-e053-d805fe0acbaa
|
85
|
|
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file e27ce427-3a7d-2581-e053-d805fe0acbaa
|
83
|
|
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility, file e27ce429-02da-2581-e053-d805fe0acbaa
|
81
|
|
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer, file e27ce429-1433-2581-e053-d805fe0acbaa
|
80
|
|
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ, file e27ce431-d28a-2581-e053-d805fe0acbaa
|
79
|
|
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer, file e27ce42b-6238-2581-e053-d805fe0acbaa
|
76
|
|
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer, file e27ce42c-e1e1-2581-e053-d805fe0acbaa
|
76
|
|
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin, file e27ce435-7e08-2581-e053-d805fe0acbaa
|
75
|
|
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours, file e27ce42e-2a00-2581-e053-d805fe0acbaa
|
71
|
|
MET mutations in cancers of unknown primary origin (CUPs)., file e27ce426-ca6b-2581-e053-d805fe0acbaa
|
70
|
|
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial, file e27ce42c-564c-2581-e053-d805fe0acbaa
|
68
|
|
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy, file e27ce432-19bb-2581-e053-d805fe0acbaa
|
66
|
|
The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation, file e27ce432-7140-2581-e053-d805fe0acbaa
|
66
|
|
BRAF V600E is a determinant of sensitivity to proteasome inhibitors., file e27ce426-ffd2-2581-e053-d805fe0acbaa
|
63
|
|
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients, file e27ce42b-6c73-2581-e053-d805fe0acbaa
|
63
|
|
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-c004-2581-e053-d805fe0acbaa
|
61
|
|
Tracking colorectal cancer evolution in time and space, file e27ce42c-1eea-2581-e053-d805fe0acbaa
|
59
|
|
Synthetic lethality screening highlights colorectal cancer vulnerability to concomitant blockade of nedd8 and egfr pathways, file e27ce432-6e6c-2581-e053-d805fe0acbaa
|
59
|
|
Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids, file e27ce432-8c4d-2581-e053-d805fe0acbaa
|
58
|
|
Kras mutations and resistance to anti-egfr treatment, file e27ce426-9d7f-2581-e053-d805fe0acbaa
|
55
|
|
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3., file e27ce426-f670-2581-e053-d805fe0acbaa
|
54
|
|
null, file e27ce430-cb75-2581-e053-d805fe0acbaa
|
53
|
|
Tumor evolution as a therapeutic target, file e27ce42c-66d9-2581-e053-d805fe0acbaa
|
52
|
| Totale |
26.214 |